anti-BCMA2

anti-BCMA2 is a chimeric antigen receptor (CAR) designed for T-cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma (MM). It is constructed with a single-chain variable fragment (scFv) derived from the C11D5.3 mouse anti-human-BCMA antibody, fused to the hinge and transmembrane regions of human CD8α, the cytoplasmic portion of the CD28 costimulatory molecule, and the cytoplasmic portion of the CD3ζ signaling molecule. This CAR enables T cells to specifically recognize and kill BCMA-expressing multiple myeloma cells, demonstrating cytokine production, proliferation, and cytotoxicity in vitro, and tumor eradication in preclinical in vivo models.